Lexicon Pharmaceuticals, Inc. (LXRX) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Lexicon Pharmaceuticals, Inc. (LXRX:NASDAQ), powered by AI.

Current Price
$1.95
Sector
Healthcare
What is the Lexicon Pharmaceuticals, Inc. stock price forecast?

Lexicon Pharmaceuticals, Inc. is currently trading at $1.95. View real-time AI analysis on Alpha Lenz.

What is Lexicon Pharmaceuticals, Inc. insider trading activity?

View the latest insider trading data for Lexicon Pharmaceuticals, Inc. on Alpha Lenz.

What is Lexicon Pharmaceuticals, Inc.'s P/E ratio?

View Lexicon Pharmaceuticals, Inc.'s valuation metrics on Alpha Lenz.

Lexicon Pharmaceuticals, Inc.

NASDAQ · LXRX
$1.95-0.01(-0.51%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Lexicon Pharmaceuticals, Inc.'s future dividend policy...
Alpha Chat Insight

Lexicon Pharmaceuticals, Inc.'s ROE is -39.7%. Explore profitability and growth together.

Ask for details

Company Overview

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Leveraging advanced gene knockout technology, the company aims to identify and develop therapies from its extensive portfolio of drug targets. Its primary mission is to create innovative pharmaceutical products that offer substantial benefits over existing treatment options, particularly in areas of unmet medical needs. Notably impacting the health and biotechnology sectors, Lexicon is involved in pivotal research for conditions such as diabetes, carcinoid syndrome, and heart diseases. With a dedication to improving patient outcomes, the company collaborates extensively within the scientific community and regulatory bodies to advance its clinical programs from the laboratory through to regulatory approval. In doing so, Lexicon Pharmaceuticals plays a significant role in the biomedical market, contributing to the ongoing development and accessibility of novel medical therapies.

CEODr. Michael S. Exton Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees103

Company Statistics

FY 2025

Profile

N/AMarket Cap
$49.80MRevenue
0.00Shares Out
103Employees

Margins

99.45%Gross
-83.09%EBITDA
-98.21%Operating
-101.08%Pre-Tax
-101.08%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

610.25%Rev 3Yr
15.72%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-20.83%ROA
-39.72%ROE
-17.38%ROIC

Financial Health

$34.33MCash & Cash Equivalents
$43.12MNet Debt
72.02%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Lexicon Pharmaceuticals, Inc. (ticker: LXRX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 103 employees.

The current price is $1.95 with a P/E ratio of -x and P/B of -x.

ROE is -39.72% and operating margin is -98.21%. Annual revenue is $50M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Lexicon Pharmaceuticals, Inc. (LXRX) Stock Forecast 2026 $1.95 — Price, Financials & Analyst Targets | Alpha Lenz